DAIC

MARCH 27, 2025

tim.hodson Thu, 03/27/2025 - 12:18 March 27, 2025 Abbott recently announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation (AFib). Today, approximately 8 million Europeans over the age of 65 are living with AFib, a number expected to double over the next 30 years.

Ablation 52

Ablation AFIB Atrial Fibrillation Electrophysiology 52

DAIC

FEBRUARY 6, 2024

The international, multi-center trial will provide clinical evaluation of Cortex's 510(k) cleared Ablamap System with electrographic flow (EGF) and newly released Ablacath Mapping Catheter basket mapping catheter to identify extra-pulmonary vein EGF sources.

Ablation 104

Ablation Atrial Fibrillation AFIB Pulmonary 104

CardiacWire

DECEMBER 17, 2023

The AFib pulsed field ablation treatment era officially began in the US last week, following the FDA approval of Medtronic’s PulseSelect Pulsed Field Ablation System for the treatment of both paroxysmal and persistent atrial fibrillation. PFA systems use electroporation (short electrical pulses) to achieve pulmonary vein isolation.

AFIB 105

AFIB Ablation Atrial Fibrillation Pulmonary 105

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

DAIC

MAY 18, 2024

Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ).

Heart Rhythm 105

Heart Rhythm Atrial Fibrillation Ablation Quality of Life 105

DAIC

JUNE 19, 2024

The pipeline of algorithms likely to clear regulatory hurdles and enter the cardiac market over the next 12-18 months include those for Pulmonary Hypertension, Cardiac Amyloidosis, Diastolic dysfunction, and Hyperkalaemia. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.

AFIB 105

AFIB Reimbursement Research Atrial Fibrillation 105

CardiacWire

NOVEMBER 6, 2024

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex might not be a household name outside of electrophysiology circles, debuting less than a year ago with $90M in funding, but it was actually formed from longtime EP mapping innovator Ablacon.

AFIB 105

AFIB Electrophysiology Ablation Technology 105